ArticleFrontiers in microbiology2022
Characterization and Genomic Analysis of a Novel Jumbo Bacteriophage vB_StaM_SA1 Infecting
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Genomic and phenotypic characterization of novel jumbo and small bacteriophages infectingMicrobiology spectrum · 2026Article
- The biology of jumbo phages.Nature communications · 2026Review
- pTJK, a rare Mammaliicoccus lentus phage with broad-host-range, antibiofilm, and synergistic interactions with antimicrobials against resistant Staphylococcaceae.Archives of microbiology · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Lifestyle shapes genome architecture and codon usage bias inFrontiers in microbiology · 2026Article
- Quorum sensing inhibits phage infection by regulating biofilm formation ofJournal of virology · 2025Article
- Isolation and characterisation of a novel Silviavirus bacteriophage promising antimicrobial agent against methicillin-resistant Staphylococcus aureus infections.Scientific reports · 2024Article
- Article
- Genomic and proteomic characterization of vB_SauM-UFV_DC4, a novel Staphylococcus jumbo phage.Applied microbiology and biotechnology · 2023Article
- Genomic characterization of the novel bacteriophage IME183, infecting Klebsiella pneumoniae of capsular type K2.Archives of virology · 2023Article
- A Multimodal Approach towards Genomic Identification of Protein Inhibitors of Uracil-DNA Glycosylase.Viruses · 2023Article
- Efficacy in Galleria mellonella Larvae and Application Potential Assessment of a New Bacteriophage BUCT700 Extensively Lyse Stenotrophomonas maltophilia.Microbiology spectrum · 2023Article
- Interactions between Jumbo Phage SA1 andMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of new antimicrobial agents is critically needed due to the alarming increase in antibiotic resistance in bacterial pathogens. Phages have been widely considered as effective alternatives to antibiotics. A novel phage vB_StaM_SA1 (hereinafter as SA1) that can infect multiple
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.